19 
for repetitive treatirent of issues. Thus, without preempting amy regulatory 
authority, the RAC would becone a foccLl point for efficiently a^ldressing recon- 
binant E)NA issues important to both science and commercicd development. Uhder 
such a regime, industry's conmitment to full compliance with RAC guidance would 
be expected to continue and be strengthened. 
lb move toward successful implementation of this role, the IBA offers two speci- 
fic suggestions. First, both the large Scade Review Working Group and the RAC 
itself would benefit by being better informed on what is occurring in industry. 
The IBA theirefore suggests that an industry representative be placed on each 
body - without voting power but with responsibility to insure that industrial 
approaches arxi perspectives are taken into accouit on decisions affecting such 
interests. If the IBA was requested to do so, the IBA would be pleased to designate 
an expert with actuad large scale recombinant experience to serve in this role. 
Secondly, the IBA believes that dialogue between the IBA amd the large Scade 
Review Working Group should continue periodically on a regular beisis. Ihe IBA 
has freely expressed views and concerns today. The IBA looks forward to contin- 
uing conminication. In light of the working group responsibility to advise 
the RAC on scale-up natters, the IBA is confident that a regular channel of 
comminication can be established vhich will promote understanding and respect 
for various points of view, vhich will sharpen issues that should be construc- 
tively addressed, and vfiich will minimize undue strains on the NIH and the 
industrial community as compatible goals are pursued. 
[505] 
